Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 in Advanced CRPC
NCT01499043Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2012
- Primary completion
- Mar 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in prostate cancer (PCa), sponsored by Daiichi Sankyo Co., Ltd.. Started May 2012; status: terminated.
02
Drugs
pexidartinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01499043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499043.